Agility in Biomanufacturing: The Key to Overcoming Uncertainty
In today’s biopharma landscape, resilience isn’t enough — CDMOs must also be agile. Agility enables clients to adjust quickly to…
BioCina Resources Hub
Curated insights, technical guides, and industry updates from a global CDMO leader.
What’s next for mRNA after COVID-19?
The pandemic proved that mRNA-based vaccines could be developed, manufactured, and distributed globally in record time. But the real promise…
Expanding LNP Applications Beyond mRNA Vaccines
Lipid nanoparticles (LNPs) have transformed how we deliver mRNA. But their role in modern medicine is just beginning. In this…
Integrated mRNA-LNP Manufacturing Services
Thousands of mRNA-based vaccines and therapies are in development, but progressing from discovery to clinical trials is far from simple.…
Integrated to Accelerate: Seamless End-to-End Biomanufacturing
Speed, complexity, and quality—it’s no longer enough to pick two. In BioCina’s latest article, senior leaders share how the company’s…
Australia as a Strategic Gateway: The Economic and Regulatory Advantages of Clinical Manufacturing Down Under
Biopharmaceutical companies are under mounting pressure to move faster, spend less, and ensure global compliance all without compromising innovation. This…
Follow us on LinkedIn
Looking for Something Specific?
If you can't find what you need, our team can provide tailored resources and program-specific information to help move your program forward.